在急性前部ST段升高心肌梗塞后,复合丹申滴剂对心脏功能的影响:一项随机试验
Bo Deng1, Sibo Wang1, Yujie Wu1
1Department of Cardiology, the First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
化合物丹申滴滴药 (CDDP) 显著改善了心脏功能,特别是左心室喷射率 (LVEF),在从急性前部ST段升高心肌梗塞 (AAMI) 恢复过来的患者中. 治疗在48周内耐受良好,没有严重的不良事件.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 综合医学是一个整体的医学.
背景情况:
- 急性前部ST段升高心肌梗塞 (AAMI) 是一个关键的心血管事件.
- 在心肌梗塞后改善心脏功能对于患者的治疗结果至关重要.
- 传统中医药化合物越来越多地被探索为心血管支持.
研究的目的:
- 评估复合丹申滴液药 (CDDP) 在AAMI患者的疗效和安全性.
- 评估CDDP对心脏功能的影响,特别是左心室喷射率 (LVEF).
- 确定CDDP在这个患者群体中的安全性.
主要方法:
- 一项随机对照试验涉及247名患者,在初级皮肤穿冠状动脉干预 (pPCI) 后患有AAMI.
- 患者被分配给接受CDDP (n=126) 或安慰剂 (n=121).
- 随访时间长达48周,监测LVEF和N-终端B型亲尿素水平.
主要成果:
- 与安慰剂相比,CDDP组在24周 (LS平均值:3.31) 和48周 (LS平均值:4.35) 显示LVEF显著增加 (P <0.001).
- 两组之间没有观察到N-终端亲B型性尿素水平的显著差异.
- 在两组中,主要不良心血管和脑血管事件的发生率相似 (6.35%对5.79%,P = 0.822),没有严重的不良事件归因于CDDP.
结论:
- 化合物丹申滴液药 (CDDP) 是耐受性良好,对患有AAMI的患者是安全的.
- 在AAMI患者中,CDDP有效改善左心室喷射率 (LVEF).
- 这些发现支持使用CDDP作为AAMI后改善心脏功能的辅助疗法.
更多相关视频
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
14:35Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Heart Failure Drugs: Inotropic Agents
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Imaging Studies for Cardiovascular System I:Echocardiography
Indications: Echocardiography is utilized to diagnose heart failure, valve disorders, and myocardial infarction. It also assesses cardiac structures' size, shape, and motion,...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
